Literature DB >> 9030597

Functional characterization of a distinct ryanodine receptor mutation in human malignant hyperthermia-susceptible muscle.

M Richter1, L Schleithoff, T Deufel, F Lehmann-Horn, A Herrmann-Frank.   

Abstract

Malignant hyperthermia is an inherited autosomal disorder of skeletal muscle in which certain volatile anesthetics and depolarizing muscle relaxants trigger an abnormally high release of Ca2+ from the intracellular Ca2+ store, the sarcoplasmic reticulum. In about 50% of cases, malignant hyperthermia susceptibility is linked to the gene encoding the skeletal muscle ryanodine receptor/Ca2+ release channel (RYR1). To date, eight point mutations have been identified in human RYR1. Although these mutations are thought to lead to an increased caffeine and halothane sensitivity in the contractile response of skeletal muscle, their functional consequences have not been investigated on the molecular level. In the present study, we provide the first functional characterization of a point mutation located in the central part of RYR1, Gly2434 --> Arg. Using high affinity [3H]ryanodine binding as the experimental approach, we show that this mutation enhances the sensitivity of RYR1 to activating concentrations of Ca2+ and to the exogenous and diagnostically used ligands caffeine and 4-chloro-m-cresol. In parallel, the sensitivity to inhibiting concentrations of Ca2+ and calmodulin was reduced, transferring the mutant Ca2+ release channel into a hyperexcitable state.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9030597     DOI: 10.1074/jbc.272.8.5256

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

Review 1.  Caffeine and excitation-contraction coupling in skeletal muscle: a stimulating story.

Authors:  A Herrmann-Frank; H C Lüttgau; D G Stephenson
Journal:  J Muscle Res Cell Motil       Date:  1999-02       Impact factor: 2.698

2.  Mutations to Gly2370, Gly2373 or Gly2375 in malignant hyperthermia domain 2 decrease caffeine and cresol sensitivity of the rabbit skeletal-muscle Ca2+-release channel (ryanodine receptor isoform 1).

Authors:  G G Du; H Oyamada; V K Khanna; D H MacLennan
Journal:  Biochem J       Date:  2001-11-15       Impact factor: 3.857

Review 3.  Cardiac and skeletal muscle disorders caused by mutations in the intracellular Ca2+ release channels.

Authors:  Silvia G Priori; Carlo Napolitano
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 4.  Stressed out: the skeletal muscle ryanodine receptor as a target of stress.

Authors:  Andrew M Bellinger; Marco Mongillo; Andrew R Marks
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

Review 5.  Genetic analysis of voltage-dependent calcium channels.

Authors:  C F Fletcher; N G Copeland; N A Jenkins
Journal:  J Bioenerg Biomembr       Date:  1998-08       Impact factor: 2.945

6.  A mutation in the transmembrane/luminal domain of the ryanodine receptor is associated with abnormal Ca2+ release channel function and severe central core disease.

Authors:  P J Lynch; J Tong; M Lehane; A Mallet; L Giblin; J J Heffron; P Vaughan; G Zafra; D H MacLennan; T V McCarthy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

7.  Arg(615)Cys substitution in pig skeletal ryanodine receptors increases activation of single channels by a segment of the skeletal DHPR II-III loop.

Authors:  E M Gallant; S Curtis; S M Pace; A F Dulhunty
Journal:  Biophys J       Date:  2001-04       Impact factor: 4.033

8.  Divergent effects of the malignant hyperthermia-susceptible Arg(615)-->Cys mutation on the Ca(2+) and Mg(2+) dependence of the RyR1.

Authors:  E M Balog; B R Fruen; N H Shomer; C F Louis
Journal:  Biophys J       Date:  2001-10       Impact factor: 4.033

9.  Voltage-dependent calcium release in human malignant hyperthermia muscle fibers.

Authors:  A Struk; F Lehmann-Horn; W Melzer
Journal:  Biophys J       Date:  1998-11       Impact factor: 4.033

Review 10.  Ryanodine receptor-mediated arrhythmias and sudden cardiac death.

Authors:  Lynda M Blayney; F Anthony Lai
Journal:  Pharmacol Ther       Date:  2009-04-01       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.